TAVIST
LOE ApproachingNDAORALTABLET
Approved
Feb 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAVIST is an oral tablet small-molecule product approved by Novartis in 1977. The specific indication and mechanism of action are not publicly detailed in available data. This is a legacy NDA product approaching loss of exclusivity.
LOE Approaching
This product is in late-stage lifecycle with moderate competitive pressure (30/100), indicating a mature brand likely managed by a smaller, cost-focused team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TAVIST offers limited career growth opportunities given its LOE-approaching status and zero currently linked positions. This role is best suited for professionals seeking to manage legacy products or transition into generic/lifecycle management strategies.
Brand ManagerField Sales Representative
Worked on TAVIST at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.